Researcher Database

FUJITA Takuya

Department / Course College of Pharmaceutical Sciences Department of Pharmacy

Title / Position Professor

Papers
1.	2023/02	Generation of Caco-2 cells with predictable metabolism by CYP3A4, UGT1A1 and CES using the PITCh system. │ Drug Metabolism and Pharmacokinetics │ 50,pp.100497 (Co-authored)
2.	2023	Early Differentiation Signatures in Human Induced Pluripotent Stem Cells Determined by Non-Targeted Metabolomics Analysis. │ Metabolites │ ,pp.in press (Co-authored)
3.	2022/11	Inhibition of Liquid–Liquid Phase Separation for Breaking the Solubility Barrier of Amorphous Solid Dispersions to Improve Oral Absorption of Naftopidil. │ Pharmaceutics │ 14 (12),pp.2664 (Co-authored)
4.	2022/08	Alleviative effects of glutamate against chemotherapeutics agent-induced intestinal mucositis. │ Journal of Physiology and Pharmacology │ 73 (4),pp.539-546 (Co-authored)
5.	2022/07/01	Mesenchymal stem cells promote IL-6 secretion and suppress the gene expression of proinflammatory cytokines in contractile C2C12 myotubes │ Biological and Pharmaceutical Bulletin │ 45 (7),pp.962-967 (Co-authored)
6.	2022/05/18	Generation of HepG2 Cells with High Expression of Multiple Drug-Metabolizing Enzymes for Drug Discovery Research Using a PITCh System. │ Cells │ 11 (10),pp.1677 (Co-authored)
7.	2022/02/15	Prediction of oral drug absorption in rats from in vitro data. │ Pharmaceutical Research │ ,pp.in press (Co-authored)
8.	2021/12/21	The Development of Biomimetic Aligned Skeletal Muscles in a Fully 3D Printed Microfluidic Device. │ Biomimetics │ 7 (1),pp.2 (Co-authored)
9.	2021/10/27	Intramuscular injection of mesenchymal stem cells activates anabolic and catabolic systems in mouse skeletal muscle. │ Scientific Reports │ 11 (1),pp.21224 (Co-authored)
10.	2021/10/16	Generation of Caco-2 cells stably expressing CYP3A4·POR·UGT1A1 and CYP3A4·POR·UGT1A1*6 using a PITCh system. │ Archives of Toxicology │ 96 (2),pp.499-510 (Co-authored)
11.	2021/05/07	Indigo enhances wound healing activity of Caco‑2 cells via activation of the aryl hydrocarbon receptor. │ Journal of Natural Medicines │ 75 (4),pp.833-839 (Co-authored)
12.	2021/03/15	Characterization of P-glycoprotein inhibitors for evaluating the effect of P-glycoprotein on the intestinal absorption of drugs. │ Pharmaceutics │ 13,pp.388 (Co-authored)
13.	2021/02/05	Relevance of Liquid-liquid Phase Separation of Supersaturated Solution in Oral Absorption of Albendazole from Amorphous Solid Dispersions. │ Pharmaceutics │ 13 (2),pp.20 (Co-authored)
14.	2021/01/30	Magnetization of mesenchymal stem cells using magnetic liposomes enhances their retention and immunomodulatory efficacy in mouse inflamed skeletal muscle. │ International Journal of Pharmaceutics │ 596,pp.120298 (Co-authored)
15.	2020/12/01	Prediction of negative food effect induced by bile micelle binding on oral absorption of hydrophilic cationic drugs. │ European Journal of Pharmaceutical Sciences │ 155,pp.105543 (Co-authored)
16.	2020/11/01	Mesenchymal stem cells after the inflammatory response of C2C12 mouse skeletal muscle cells. │ Biological and Pharmaceutical Bulletin │ 43 (11),pp.1785-1791 (Co-authored)
17.	2020/09/03	Bottom-up physiologically-based oral absorption modeling of free weak base drugs. │ Pharmaceutics │ 12 (9),pp.844 (Co-authored)
18.	2020/06	Hepatic expression of the Na⁺-coupled citrate transporter (NaCT/Slc13a5) and cellular uptake of citrate in a mouse model of type 1 diabetes induced by streptozotocin. │ BPB Reports │ 3 (3),pp.97-101 (Co-authored)
19.	2020/06	The impact of breast cancer resistance protein (BCRP/ABCG2) on drug transport across Caco-2 cell monolayers │ Drug Metabolism and Disposition │ 48 (6),pp.491-498 (Co-authored)
20.	2020/04/09	Transport characteristics of 5-aminosalicylic acid into colonic epithelium: Involvement of sodium-coupled monocarboxylate transporter SMCT1-mediated transport system. │ Biochemical and Biophysical Research Communications │ 524 (3),pp.561-566 (Co-authored)
21.	2020/04/01	Transport characteristics of 5-aminosalicylic acid derivatives conjugated with amino acids via human H⁺-coupled oligopeptide transporter PEPT1. │ Biological and Pharmaceutical Bulletin │ 43 (4),pp.697-706 (Co-authored)
22.	2020/04	Impact of degree of supersaturation on the dissolution and oral absorption behaviors of griseofulvin amorphous solid dispersions. │ Journal of Drug Delivery Science and Technology │ 56,pp.101172 (Co-authored)
23.	2020/03	Prediction characteristics of oral absorption simulation software evaluated using structurally diverse low solubility drugs. │ Journal of Pharmaceutical Sciences │ 109 (3),pp.1403-1416 (Co-authored)
24.	2020/01	Assessment of contribution of BCRP to intestinal absorption of various drugs using portal-systemic blood concentration difference model in mice. │ Pharmacological Research and Perspective │ 8 (1),pp.e00544 (Co-authored)
25.	2019/12	Enhanced macrophage delivery to the colon using magnetic lipoplexes with a magnetic field. │ Drug Delivery │ 26 (1),pp.935-943 (Co-authored)
26.	2019/12	Protein kinase C regulates the citrate transport via Na⁺-coupled citrate transporter NaCT in HepG2 cells. │ BPB Reports │ 2 (6),pp.134-140 (Co-authored)
27.	2019/08/05	Harmonizing solubility measurement to lower inter-laboratory variance - progress of consortium of biopharmaceutical tools (CoBiTo) in Japan. │ ADMET DMPK │ 7 (3),pp.183-195 (Co-authored)
28.	2019/08	Prediction Accuracy of Mechanism-Based Oral Absorption Model for Dogs. │ Journal of Pharmaceutical Sciences │ 108 (8),pp.2728-2736 (Co-authored)
29.	2019/05	An Openable Artificial Intestinal Tract System Enables the Evaluation of Drug Absorption in Caco-2 Cells through the Reduction in Thickness of the Unstirred Water Layer. │ Biological and Pharmaceutical Bulletin │ 42 (5),pp.840-844 (Co-authored)
30.	2018/07	Pharmaceutical stability of colloidal saccharated iron oxide injection in normal saline. │ Journal of Pharmaceutical Health Care and Sciences │ 4,pp.Article number: 21 (Co-authored)
31.	2018/01	Effect of surface charge, particle size, and modification by polyethylene glycol of liposomes on their association with Caco-2 cells across an unstirred water layer. │ Pharmazie │ 73 (1),pp.3-8 (Co-authored)
32.	2017/12	Influence of physicochemical properties and PEG modification of magnetic liposomes on their interaction with intestinal epithelial Caco-2 Cells. │ Biological and Pharmaceutical Bulletin │ 40 (12),pp.2166-2174 (Co-authored)
33.	2017/11	Development of magnetic anionic liposome/atelocollagen complexes for efficient magnetic drug targeting. │ Drug Delivery │ 24 (1),pp.1740-1749 (Co-authored)
34.	2017/01	Pharmacokinetic modeling and Monte Carlo simulation to predict interindividual variability in human exposure to oseltamivir and its active metabolite, Ro 64-0802. │ The AAPS Journal │ 19 (1),pp.286-297 (Co-authored)
35.	2016/11	Dextran sodium sulfate alters cytokine production in macrophages in vitro. │ Pharmazie │ 71 (11),pp.619-624 (Co-authored)
36.	2016/08	Effect of mechanical agitation on cationic liposome transport across an unstirred water layer in Caco-2 cells. │ Biological and Pharmaceutical Bulletin │ 39 (8),pp.1293-1299 (Co-authored)
37.	2015/08	An openable artificial intestinal tract system for the in vitro evaluation of medicines. │ Microsystems &Nanoengineering │ 1,pp.15015 (Co-authored)
38.	2013/01	Studies on the Intestinal Absorption Characteristics of Sulfasalazine, a Breast Cancer Resistance Protein (BCRP) Substrate. │ Drug Metabolism and Pharmacokinetics │ 28 (1),pp.71-74 (Co-authored)
39.	2012/07	Pharmacokinetic interaction study of sulfasalazine in healthy subjects and the impact of curcumin as an in vivo inhibitor of BCRP. │ British Journal of Pharmacology │ 166 (6),pp.1793-1803 (Co-authored)
40.	2012/02	Extra-renal Elimination of Uric Acid via Intestinal Efflux Transporter BCRP/ABCG2. │ PLoS ONE │ 7 (2),pp.e30456 (Co-authored)
41.	2011/12	Quantitative evaluation of the impact of active efflux by P-gp and Bcrp at the BBB on the predictability of the unbound concentrations of drugs in the brain using cerebrospinal fluid concentration as surrogate. │ Journal Pharmacology and Experimental Therapeutics │ 339 (3),pp.935-944 (Co-authored)
42.	2011/06	Intranasal immunization with poly(γ-glutamic acid) nanoparticles entrapping antigenic proteins can induce potent tumor immunity. │ Journal of Controlled Release │ 152 (2),pp.310-316 (Co-authored)
43.	2010/11	Absorption and safety of alendronate, a nitrogen-containing bisphosphonate, after intrapulmonary administration in rats. │ International Journal of Pharmaceutics │ 400 (1-2),pp.124-130 (Co-authored)
44.	2009/12	Amino acids suppress apoptosis induced by sodium laurate, an absorption enhancer. │ Journal of Pharmaceutical Sciences │ 98 (12),pp.4629-4638 (Co-authored)
45.	2008/12	Modulating effect of polyethylene glycol on the intestinal transport and absorption of prednisolone, methylprednisolone and quinidine in rats by in-vitro and in-situ absorption studies. │ Journal of Pharmacy and Pharmacology │ 60 (12),pp.1633-1644 (Co-authored)
46.	2008/11	Oligoarginine-based prodrugs with self-cleavable spacers for intestinal absorption. │ Chemical and Pharmaceuticsl Bulletin │ 56 (11),pp.1515-1520 (Co-authored)
47.	2008/10	A transcutaneous vaccination system using a hydrogel patch for viral and bacterial infection │ Journal of Cotrolled Release │ 131 (2),pp.113-120 (Co-authored)
48.	2008/07	Improvement of intestinal absorption of insulin and water-soluble macromolecular compounds by chitosan oligomers in rats │ International Journal of Pharmaceutics │ 359 (1-2),pp.70-78 (Co-authored)
49.	2008/05	Factors involved in the maturation of murine dendritic cells transduced with adenoviral vector variants. │ Viology │ 374 (2),pp.411-420 (Co-authored)
50.	2008/04	Improvement of intestinal absorption of water-soluble macromolecules by various polyamines: Intestinal mucosal toxicity and absorption-enhancing mechanism of spermine. │ International Jouranl of Pharmaceutics │ 354 (1-2),pp.126-134 (Co-authored)
51.	2008/03	Functional characterization and cloning of amino acid transporter B^0,+ (ATB^0,+) in primary cultured rat pneumocytes. │ Journal of Cellular Physiology │ 214 (3),pp.645-654 (Co-authored)
52.	2008/02	P-glycoprotein restricts the penetration of oseltamivir across the blood-brain barrier │ Drug Metabolism and Disposition │ 36 (2),pp.427-434 (Co-authored)
53.	2008/01	Creation and X-ray structure analysis of the tumor necorsis factor receptor-1 selective mutant of a TNF-α antagosist. │ Journal of Biological Chemistry │ ,pp.998-1007 (Co-authored)
54.	2008/01	Oseltamivir (Tamiflu^TM) efflux transport at the blood-brain barrier via P-glycoprotein │ Drug Metabolism and Disposition │ 36 (1),pp.6-9 (Co-authored)
55.	2007/11	CC-chemokine ligand 17 gene therapy induces tumor regression through augmentation of tumor-infiltrating immune cells in a murine model of pre-existing CT26 colon carcinoma. │ International Journal of Cancer │ 121,pp.2013-2022 (Co-authored)
56.	2007/11	Interaction of penton base Arg-Gly-Asp motifs with integrins is crucial for adenovirus serotype 35 vector transduction in human hematopoietic cells. │ Gene Therapy │ 14,pp.1525-1533 (Co-authored)
57.	2007/09	Development of oligoarginine-drug conjugates linked to new peptidic self-cleavable spacers towards effective intestinal absorption. │ Bioorganic and Medicinal Chemistry Letters │ 17,pp.5129-5132 (Co-authored)
58.	2007/09	Improvement of pulmonary absorption of inuslin and other water-soluble compounds by polyamines in rats. │ Journal of Controlled Release │ 122,pp.94-101 (Co-authored)
59.	2007/01	102 Creation of TNF receptor1 selective mutant TNF using phage display syste. │ Cytokine │ 39 (1),pp.28 (Co-authored)
60.	2006/06	Excellent absorption enhancing characteristics of NO donors for improving the intestinal absorption of poorly absorbable compound compared with conventional absorption enhancers. │ Drug Metabolism and Pharmacokinetics │ 21 (3),pp.222-229 (Co-authored)
61.	2006/06	Identity of the high-affinity sodium/carboxylate cotransporter NaC3 as the N-acetyl-L-aspartate transporter. │ Advances in Experimental Medicine and Biology │ 576,pp.67-76 (Co-authored)
62.	2006/06	What kinds of substrates show P-glycoprotein- dependent intestinal absorption? Comparison of verapamil with vinblastine. │ Drug Metabolism and Pharmacokinetics │ 21 (3),pp.238-244 (Co-authored)
63.	2006/04	Colon-specific delivery and enhanced colonic absorption of [Asu^1,7] Eel calcitonin using chitosan capsules containing various additives in rats. │ Journal of Drug Targeting │ 14 (3),pp.165-172 (Co-authored)
64.	2006/04	Functional and molecular identification of sodium- coupled dicarboxylate transporters in primary cultured cerebrocortical astrocytes and neurons. │ Journal of Neurochemistry │ 97 (1),pp.162-173 (Co-authored)
65.	2006/04	Functional characterization of Na⁺-coupled citrate transporter NaC2/NaCT expressed in primary cultures of neurons from mouse cerebral cortex. │ Brain Research │ 1081 (1),pp.92-100 (Co-authored)
66.	2006/04	Functional expression of taurine transporter and its up-regulation in developing neurons from mouse cerebral cortex. │ Pharmaceutical Research │ 23 (4),pp.689-696 (Co-authored)
67.	2006/04	Modulation of intestinal P-glycoprotein function by polyethylene glycols and their derivatives by in vitro transport and in situ absorption studies. │ International Journal of Pharmaceutics │ 313 (1),pp.49-56 (Co-authored)
68.	2006/04	Tumor suppressive efficacy through augmentation of tumor-infiltrating immune cells by intratumoral injection of chemokine-expressing adenoviral vector. │ Cancer Gene Therapy │ 13 (4),pp.393-405 (Co-authored)
69.	2006/03	Functional expression of metabotropic γ-aminobutyric acid GABA_B receptor in primary culture of astrocytes from rat cerebral cortex. │ Biochemical and Biophysical Research Communications │ 341 (3),pp.874-881 (Co-authored)
70.	2006/02	Functional characterization of Zn²⁺-sensitive GABA transporter expressed in primary cultures of astrocytes from rat astrocytes. │ Brain Research │ 1075 (1),pp.99-108 (Co-authored)
71.	2006/01	Functional characteristics of H⁺-dependent nicotinic acid transport in primary cultures of astrocytes from rat cerebral cortex. │ Neuroscience Letters │ 392 (3),pp.207-212 (Co-authored)
72.	2006/01	Functional characterization of Na⁺-independent choline transport in primary cultures of neurons from mouse cerebral cortex. │ Neuroscience Letters │ 393 (2-3),pp.216-221 (Co-authored)
73.	2005/11	Chitosan oligomers as potential and safe absorption enhnacers for improving the pulmonary absorption of interferon-α in rats. │ Journal of Pharmaceutical Sciences │ 94 (11),pp.2432-2440 (Co-authored)
74.	2005/09	Nitric oxide donors can enhance the intestinal transport and absorption of insulin and [Asu^1,7]-eel calcitonin in rats. │ Journal of Controlled Release │ 106 (3),pp.283-293 (Co-authored)
75.	2005/05	A Prostacyclin analog prevents radiocontrast nephropathy via phosphorylation of cyclic AMP response element binding protein. │ American Journal of Pathology │ 166 (5),pp.1333-1342 (Co-authored)
76.	2005/05	Functional linkage of H⁺/peptide transporter PEPT2 and Na⁺/H⁺ exchanger in primary cultures of astrocytes from mouse cerebral cortex. │ Brain Research │ 1044 (1),pp.31-41 (Co-authored)
77.	2005/05	Transport characteristics of N-acetyl-L-aspartate in rat astrocytes: Involvement of sodium-coupled high affinity carboxylate transporter NaC3/NaDC3 mediated transport system. │ Journal of Neurochemistry │ 93 (3),pp.706-714 (Co-authored)
78.	2005/04	Carrageenans can regulate the pulmonary absorption of antiasthmatic drugs and their retention in the rat lung tissues without any membrane damage. │ International Journal of Pharmaceutics │ 293 (1-2),pp.63-72 (Co-authored)
79.	2005/04	Functional characterization and adaptive regulation of Na⁺-dependent neutral amino acid transporter SNAT2/ATA2 in normal human astrocytes under amino acid starved condition. │ Neuroscience Letters │ 378 (2),pp.70-75 (Co-authored)
80.	2005/04	Functional regulation of Na⁺-dependent neutral amino acid transporter ASCT2 by S-nitrosothiols and nitric oxide in human intestinal cell line Caco-2. │ FEBS Letters │ 579 (11),pp.2499-2506 (Co-authored)
81.	2005/04	Improvement of absorption enhancing effects of n-dodecyl-β-D-malto-pyranoside by its colon-specific delivery using chitosan capsules. │ International Journal of Pharmaceutics │ 293 (1-2),pp.127-135 (Co-authored)
82.	2005/01	Augmentation of the migratory ability of DC-based vaccine into regional lymph nodes by efficient CCR7 gene transduction. │ Gene Therapy │ 12 (2),pp.129-139 (Co-authored)
83.	2005/01	Immunological properties and vaccine efficacy of murine dendritic cells simultaneously expressing melanoma- associated antigen and interleukin-12. │ Cancer Gene Therapy │ 12 (1),pp.72-83 (Co-authored)
84.	2004/09	Control of pulmonary absorption of water-soluble compounds by various viscous vehicles. │ International Journal of Pharmaceutics │ 282 (1-2),pp.141-149 (Co-authored)
85.	2004/04	Anti-tumor activity of chemokine is affected by both kinds of tumors and the activation state of the host's immune system: implications for chemokine-based cancer immunotherapy. │ Biochemical and Biophysical Research Communications │ 317 (1),pp.68-76 (Co-authored)
86.	2004/04	Functional expression of constitutive nitric oxide synthase regulated by voltage-gated Na⁺- and Ca²⁺- channels in cultured human astrocytes. │ Glia │ 46 (1),pp.53-62 (Co-authored)
87.	2004/04	Modulation of intestinal P-glycoprotein function by cremophor EL and other surfactants by an in vitro diffusion chamber method using the isolated rat intestinal membranes. │ Journal of Pharmaceutical Sciences │ 93 (4),pp.877-885 (Co-authored)
88.	2004/01	Functional characterization of brain peptide transporter in rat cerebral cortex: Identification of the high affinity type H⁺/peptide transporter PEPT2. │ Brain Research │ 997 (1),pp.52-61 (Co-authored)
89.	2003/10	Dendritic cells transduced with gp100 gene by RGD fiber-mutant adenovirus vectors are highly efficacious in generating anti-B16BL6 melanoma immunity in mice. │ Gene Therapy │ 10 (22),pp.1891-1901 (Co-authored)
90.	2003/06	Gabapentin blocks L-type and P/Q-type Ca²⁺ channels involved in depolarization- stimulated nitric oxide synthase activity in primary culture of neurons from mouse cerebral cortex. │ Pharmaceutical Research │ 26 (6),pp.1365-1367 (Co-authored)
91.	2003/06	Intradermal concentration of hydroquinone after application of hydroquinone ointments is higher than its cytotoxic concentration. │ Biological and Pharmaceutical Bulletin │ 26 (6),pp.1365-1367 (Co-authored)
92.	2003/05	A comparison of Ca²⁺ channel blocking mode between gabapentin and verapamil: Implication for protection against hypoxic injury in rat cerebrocortical slices. │ British Journal of Pharmacology │ 139 (2),pp.435-443 (Co-authored)
93.	2003/05	Gene transduction efficiency and maturation status in mouse bone marrow-derived dendritic cells infected with conventional or RGD fiber- mutant adenovirus vectors. │ Cancer Gene Therapy │ 10 (5),pp.421-431 (Co-authored)
94.	2003/01	Effects of various storage conditions and alterations of antioxidant contents on chromatic aberration of hydroquinone ointment. │ Biological and Pharmaceutical Bulletin │ 26 (1),pp.120-122 (Co-authored)
95.	2003/01	Enhanced permeability of phenylalanyl-glycine (Phe-Gly) across the intestinal membranes by chemical modification with various fatty acids. │ Drug Metabolism and Pharmacokinetics │ 18 (1),pp.23-32 (Co-authored)
96.	2003/01	Enhanced transdermal delivery of phenylalanyl- glycine by chemical modification with various fatty acids. │ International Journal of Pharmaceutics │ 250 (1),pp.119-128 (Co-authored)
97.	2002/10	Halothane attenuates the cerebroprotective action of several Na⁺- and Ca²⁺- channel blockers via reversal of their ion channel blockade. │ European Journal of Pharmacology │ 452 (2),pp.175-181 (Co-authored)
98.	2002/04	Chitosan capsules for colon-specific drug delivery: enhanced localization of 5-aminosalicylic acid in the large intestine accelerates healing of TNBS-induced colitis in rats. │ Journal of Controlled Release │ 82 (1),pp.51-61 (Co-authored)
99.	2002/03	Tumor necrosis factorα‐gene therapy for an established murine melanoma using RGB (Arg‐Gly‐Asp) fiber‐mutant adenovirus vectors │ Cancer Science │ 93 (4),pp.436-444 (Co-authored)
100.	2002/01	Pharmaceutical and clinical assessment of hydroquinone ointment prepared by extemporaneous nonsterile compounding. │ Biological and Pharmaceutical Bulletin │ 25 (1),pp.92-96 (Co-authored)
101.	2001/11	Efficient antigen gene transduction using Arg-Gly-Asp fiber-mutant adenovirus vectors can potentiate antitumor vaccine efficacy and maturation of murine dendritic cells. │ Cancer Research │ 61 (21),pp.7913-7919 (Co-authored)
102.	2001/10	Absorption of water-soluble compounds with different molecular weights and [Asu^1,7]-eel calcitonin from various mucosal administration sites. │ Journal of Controlled Release │ 76 (3),pp.364-373 (Co-authored)
103.	2001/08	Effects of lipofection-antigen complexes on major histocompatibility comples class I-restricted antigen presentation pathway in murine dendritic cells and on dendritic cell maturation. │ Biochimica et Biophysica Acta │ 1527 (1),pp.97-101 (Co-authored)
104.	2001/06	Administration route- dependent vaccine efficiency of murine dendritic cells pulsed with antigens. │ British Journal of Cancer │ 84 (11),pp.1564-1570 (Co-authored)
105.	2001/06	Role of nuclear factor-κB in gastric ulcer healing in rats. │ American Journal of Physiology- Gastrointestinal and Liver Physiology │ 280 (6),pp.G1296-G1304 (Co-authored)
106.	2001/05	Involvement of transporter recruitment as well as gene expression in the substrate- induced adaptive regulation of amino acid transport system A. │ Biochimica et Biophysica Acta │ 1512 (1),pp.15-21 (Co-authored)
107.	2001/04	Evaluation of insulin permeability and effects of absorption enhancers on its permeability by an in vitro pulmonary epithelial system using Xenopus pulmonary membrane. │ Biological and Pharmaceutical Bulletin │ 24 (4),pp.378-384 (Co-authored)
108.	2001/03	Efficient gene delivery into dendritic cells by fiber-mutant adenovirus vectors. │ Biochemical and Biophysical Research Communications │ 282 (1),pp.173-176 (Co-authored)
109.	2001/01	Enhanced absorption of insulin and (Asu^1,7)eel- calcitonin using novel azopolymer-coated pellets for colon-specific drug delivery. │ Journal of Pharmaceutical Sciences │ 90 (1),pp.89-97 (Co-authored)
110.	2001/01	FR167653, a p38 mitogen- activated protein kinase inhibitor, prevents Helicobacter pylori-induced gastritis in Mongolian gerbils. │ Journal of Pharmaceology and Experimental Therapeutics │ 296 (1),pp.48-56 (Co-authored)
111.	2001/01	Modulation of intestinal permeability by nitric oxide donors: implications in intestinal delivery of poorly absorbable drugs. │ Journal of Pharmacology and Experimental Therapeutics │ 296 (1),pp.84-90 (Co-authored)
112.	2000/12	Development of novel lipophilic derivatives of DADLE (leucine enkephaline analogue): Intestinal permeability characteristics of DADLE derivatives in rats. │ Pharmaceutical Research │ 17 (12),pp.1461-1467 (Co-authored)
113.	2000/10	NSAID-induced acute gastric injury in Helicobacter pylori gastritis in Mongloian gerbils. │ European Journal of Pharmacology │ 406 (3),pp.461-468 (Co-authored)
114.	2000/10	Role of cyclooxygenase-2 in Helicobacter pylori-induced gastritis in Mongolian gerbils. │ American Journal of Physiology- Gastrointestinal and Liver Physiology │ 279 (4),pp.G791-G798 (Co-authored)
115.	2000/06	Electrophysilogical characteristics of Caco-2 cells using microelectrode: Application to evaluate the absorption enhancers. │ Biological and Pharmaceutical Bulletin │ 23 (6),pp.738-742 (Co-authored)
116.	2000/01	Colon-specific delivery of peptide drugs and anti- inflammatory drugs using chitosan capsules. │ S.T.P. Pharmacy and Sciences │ 10 (1),pp.23-34 (Co-authored)
117.	1999/11	Enhanced permeability of insulin across the rat intestinal membrane by various absorption enhancers: Their intestinal mucosal toxicity and absorption enhancing mechanism of n-lauryl-beta-D-maltopyranoside. │ Journal of Pharmacy and Pharmacology │ 51 (11),pp.1241-1250 (Co-authored)
118.	1999/10	Validation of pharmacokinetic model for colon-specific drug delivery system and therapeutic effects of chitosan capsules containing 5-aminosalicylic acid on 2,4,6-trinitrobenzenesulfonic acid-induced colitis in rats. │ Journal of Pharmacy and Pharmacology │ 51 (10),pp.1107-1112 (Co-authored)
119.	1999/08	Electrophysiological study on enhanced mechanism of intestinal transport of water-soluble compounds by antibiotic peptide bacitracin. │ Biological and Pharmaceutical Bulletin │ 22 (8),pp.841-845 (Co-authored)
120.	1999/08	Interaction of kyotorphin and brain peptide transporter in synaptosomes prepared from rat cerebellum: Implication of high affinity type H⁺/peptide transpoorter PEPT2 mediated transport system. │ Neuroscience Letters │ 271 (2),pp.117-120 (Co-authored)
121.	1999/08	Sigma receptor ligand- induced up-regulation of the H⁺/peptide transporter PEPT1 in the human intestinal cell line Caco-2. │ Biochemical and Biophysical Research Communications │ 261 (2),pp.242-246 (Co-authored)
122.	1999/06	Development of an oral formulation of azetirelin, a new thyrotropin-releasing hormone (TRH) analogue, using n-lauryl-beta-D-maltopyranoside as an absorption enhancer. │ Biological and Pharmaceutical Bulletin │ 22 (6),pp.611-615 (Co-authored)
123.	1999/05	Colon-specific delivery of budesonide with azopolymer-coating pellets: Therapeutic effects of budesonide with a novel dosage form against 2,4,6-trinitrobenzenesulfonic acid-induced ulcerative colitis in rats. │ Journal of Phamacy and Pharmacology │ 51 (5),pp.257-261 (Co-authored)
124.	1999/03	Colon specific delivery of R68070, a new thromboxane synthase inhibitor, using chitosan capsules: Therapeutic effects of 2,4,6-trinitrobenzene sulfonic acid-induced colitis in rats. │ Life Sciences │ 64 (13),pp.1155-1162 (Co-authored)
125.	1999/03	Transport kinetics of leucine-enkephalin across Caco-2 monolayer: Quantitative analysis for contribution of enzymatic and transport barriers. │ Life Sciences │ 64 (14),pp.1243-1252 (Co-authored)
126.	1998/09	Permeability characteristics of acyl-tetragastrins across the intestinal membranes using the Caco-2 monolayer system. │ Pharmaceutical Research │ 15 (9),pp.1387-1392 (Co-authored)
127.	1998/08	Effects of various protease inhibitors on the stability and permeability of [D-Ala², D-Leu⁵]enkephalin in the rat intestine: Comparison with leucin enkephalin. │ Journal of Pharmaceutica Sciences │ 87 (8),pp.448-452 (Co-authored)
128.	1998/08	Use of protease inhibitors to improve calcitonin absorption from the small and large intestine in rats. │ Journal of Pharmacy and Pharmacology │ 50 (8),pp.913-920 (Co-authored)
129.	1998/06	Effectiveness and toxicity screening of various absorption enhancers using Caco-2 cell monolayers. │ Biological and Pharmaceutical Bulletin │ 21 (6),pp.615-620 (Co-authored)
130.	1998/06	Two oligopepite transporters from Caenorhabditis elegans. molecular cloning and functional expression. │ Biochemical Journal │ 332 (2),pp.565-572 (Co-authored)
131.	1998/05	Identification of a potential substrate binding domain in the mammalian peptide transporters PEPT1 and PEPT2 using PEPT1-PEPT2 and PEPT2-PEPT1 chimeras. │ Biochemical and Biophysical and Research Communications │ 246 (1),pp.39-44 (Co-authored)
132.	1998/03	Cloning and functional expression of a cDNA encoding a mammalian sodium-dependent vitamin transporter mediating the uptake of pantothenate, biotin, and lipoate. │ Journal of Biological Chemistry │ 273 (13),pp.7501-7506 (Co-authored)
133.	1998/02	Exon-intron structure, analysis of promoter region, and chromosomal localization of the human type I sigma receptor gene. │ Journal of Neurochemistry │ 70 (2),pp.443-451 (Co-authored)
134.	1997/12	Enhancement of the small intestinal uptake of phenylalanylglycine via a H⁺/oligopeptide transport system via chemical modification with fatty acids. │ Life Sciences │ 61 (25),pp.2455-2465 (Co-authored)
135.	1997/08	Metabolism of azetirelin, a new thyrotropin-releasing hormone (TRH) analogue, by intestinal microorganism. │ Pharmaceutical Research │ 14 (8),pp.1004-1007 (Co-authored)
136.	1997/05	Pharmacokinetic analysis of scavenger receptor-mediated uptake of anionized proteins in the isolated perfused rat liver. │ International Journal of Pharmaceutics │ 151 (1),pp.15-26 (Co-authored)
137.	1997/05	Pharmacokinetics of mitomycin C (MMC) after intraperitoneal administration of MMC-gelatin gel and its anti-tumor effects against Sarcoma-180 bearing mice. │ Journal of Drug Targeting │ 4 (5),pp.289-296 (Co-authored)
138.	1997/05	Potential for lymphatic targeting of peptides. │ Journal of Controlled Release │ 46 (1-2),pp.157-164 (Co-authored)
139.	1997/02	Degradation of insulin and calcitonin and their protection by various protease inhibitors in rat cecal contents: Implications in peptide delivery to the colon. │ Journal of Pharmacy and Pharmacology │ 49 (2),pp.164-168 (Co-authored)
140.	1997/02	Selective delivery of 5-fluorouracil (5-FU) to i.p. tissues using 5-FU microspheres in rat. │ Anti-Cancer Drugs │ 8 (2),pp.182-188 (Co-authored)
141.	1997/01	Calcein is excreted from the intestinal mucosal cell membrane by the active transport system. │ Life Sciences │ 60 (4-5),pp.307-313 (Co-authored)
142.	1996/12	Effectiveness and toxicity screening of various absorption enhancers in the large intestine: Intestinal absorption of phenol red and protein and phospholipid release from the intestinal membrane. │ Biological and Pharmaceutical Bulletin │ 19 (12),pp.1618-1621 (Co-authored)
143.	1996/11	Pharmacological effects of 5-fluorouracil microspheres on peritoneal carcinomatosis in animals. │ British Journal of Cancer │ 74 (9),pp.1392-1396 (Co-authored)
144.	1996/08	Absorption enhancement effects of protease inhibitors on the absorption of phenol red and fluorescein isothiocyanate dextrans from the small and large intestine in rats. │ Journal of Pharmaceutical Sciences │ 85 (8),pp.858-862 (Co-authored)
145.	1996/08	Enhancement of intestinal transport of throtropin-releasing hormone via a carrier-mediated transport system by chemical modification with lauric acid. │ Biochimica Biophysica et Acta │ 1283 (1),pp.119-126 (Co-authored)
146.	1996/08	Pulmonary absorption enhancement of peptides by absorption enhancers and protease inhibitors. │ Journal of Controlled Release │ 41 (1-2),pp.57-67 (Co-authored)
147.	1996/08	Transport of drugs across the Xenopus pulmonary membrane and their absorption enhancement by various absorption enhancers. │ Pharmaceutical Research │ 13 (8),pp.1257-1261 (Co-authored)
148.	1996/05	Imrovement of intestinal absorption of human calcitonin by chemical modification with fatty acids: synergenic effects of acylation and absorption enhancers. │ International Journal of Pharmacetics │ 134 (1-2),pp.47-54 (Co-authored)
149.	1996/05	Lymphatic transfer of macromolecules after intrapulmonary administration in the presence or absence of various absorption enhancers in rats. │ Pharmazie │ 51 (5),pp.331-336 (Co-authored)
150.	1996/02	Effectiveness and toxicity screening of various absorption enhancers in the small intestine: Effect of absorption enhancers on the intestinal absorption of phenol red and the release of protein and phospholipid from the intestinal membrane. │ Journal of Pharmacy and Pharmacology │ 48 (2),pp.1285-1289 (Co-authored)
151.	1995/11	Molecular weight-dependent lymphatic transfer of fluorescein isothiocyanate-labeled dextrans after intrapulmonary administration and effect of various absorption enhancers on the lymphatic transfer of drugs in rats. │ Journal of Drug Targeting │ 3 (4),pp.263-271 (Co-authored)
152.	1995/10	Improvement of transdermal delivery of tetragastrin by lipophilic modification with fatty acids. │ Journal of Pharmacy and Pharmacology │ 47 (10),pp.808-811 (Co-authored)
153.	1995/08	Control of disposition characteristics of proteins by direct cationization. │ Pharmaceutical Sciences │ 1 (8),pp.371-375 (Co-authored)
154.	1995/08	Synergistic anti-tumor effects of mitomycin C and bile salts against L1210 cells. │ Biological and Pharmaceutical Bulletin │ 18 (8),pp.1109-1113 (Co-authored)
155.	1995/07	Intestinal absorption of azetirelin, a new thyrotropin-releasing hormone (TRH) analogue. II. In situ and in vitro absorption characteristics of azetirelin from the rat intestine. │ Biological and Pharmaceutical Bulletin │ 18 (7),pp.976-979 (Co-authored)
156.	1995/06	Absorption characteristics of chemically modified-insulin derivatives with various fatty acids in the small and large intestine. │ Journal of Pharmaceutical Sciences │ 84 (6),pp.682-687 (Co-authored)
157.	1995/06	Metabolisms of peptide drugs by the microorganisms in rat cecal contents. │ Biological and Pharmaceutical Bulletin │ 18 (6),pp.929-931 (Co-authored)
158.	1995/06	Susceptibility of insulin to proteolysis in rat lung homogenate and its protection from proteolysis by various protease inhibitors. │ Biological and Pharmaceutical Bulletin │ 18 (6),pp.891-894 (Co-authored)
159.	1995/05	Comparison of permeability of macromolecular drugs across clutured intestinal and alveolar epithelial monolayers. │ Pharmaceutical Sciences │ 1 (5),pp.231-234 (Co-authored)
160.	1995/05	Does bacitracin have an absorption-enhancing effect in the intestine? │ Biological and Pharmaceutical Bulletin │ 18 (5),pp.794-796 (Co-authored)
161.	1994/12	Enhancement permeability of tetragastrin across the intestinal membrane and its reduced degradation by acylation with various fatty acids in rats. │ Journal of Pharmacology and Experimental Therapeutics │ 271 (3),pp.1509-1513 (Co-authored)
162.	1994/10	Effects of various protease inhibitors on the intestinal absorption and degradation of insulin in rats. │ Pharmaceutical Research │ 11 (10),pp.1496-1500 (Co-authored)
163.	1994/09	Intestinal Absorption of azetirelin, a new thyrotropin-releasing hormone (TRH) analogue I: Possible factors for the low bioavailability in rats. │ Biological and Pharmaceutical Bulletin │ 17 (9),pp.1256-1261 (Co-authored)
164.	1994/08	Stability of novel acyl derivatives of insulin in the small intestine: Relative importance of insulin association characteristics in aqueous solution. │ Pharmaceutical Research │ 11 (8),pp.1115-1120 (Co-authored)
165.	1994/07	Susceptibility of ebiratide to proteloysis in rat intestinal fluid and homogenates and its protection by various protease inhibitors. │ Life Sciences │ 55 (9),pp.677-683 (Co-authored)
166.	1994/04	Pharmacokinetics of succinylated proteins and dextran sulfate in mice: Implications for hepatic targeting of protein drugs by direct succinylation via scavenger receptors. │ International Journal of Pharmaceutics │ 105 (1),pp.19-29 (Co-authored)
167.	1994/02	Control of in vivo fate of albumin utilizing combined chemical modification. │ Journal of Drug Targeting │ 2 (2),pp.157-165 (Co-authored)
168.	1993/10	Development of new lipophilic derivatives of tetragastrin: Physicochemical characteristics and intestinal absorption of acyl-tetragastrin derivatives in rats. │ Pharmaceutical Research │ 10 (10),pp.1488-1492 (Co-authored)
169.	1993/03	Synthesis and pharmacokinetics of a new liver-specific carrier, glycosylated carboxylmethyl-dextran, and its application to drug targeting. │ Pharmaceutical Research │ 10 (3),pp.1253–1261 (Co-authored)
170.	1992/12	Targeted delivery of human recombinant superoxide dismutase by chemical modification with mono- and polysaccharide derivatives. │ Journal of Pharmacology and Experimental Therapeutics │ 263 (3),pp.1847-1854 (Co-authored)
171.	1992/11	Therapeutic effects of superoxide dismutase derivatives modified with mono- or polysaccharides on hepatics injury induced by ischemia/reperfusion. │ Biochemical and Biophysical Research Communications │ 189 (3),pp.191-196 (Co-authored)
172.	1992/09	Pharmacokinetics of receptor-mediated hepatic uptake of glycosylated albumin in mice. │ International Journal of Pharmaceutics │ 85 (1-3),pp.75-85 (Co-authored)
173.	1991/11	Tissue distribution of ¹¹¹In-labeled uricase conjugates with charged dextrans and polyethylene glycol. │ Journal of Pharmacobio-Dynamics │ 14 (11),pp.623-629 (Co-authored)
174.	1990/07	Biochemical and biopharmaceutical properties of macromolecular conjugates of uricase with dextran and polyethylene glycol. │ Chemical and Pharmaceutical Bulletin │ 38 (7),pp.2053-2056 (Co-authored)
175.	1990/04	Disposition characteristics of macromolecules in tumor-bearing mice. │ Pharmaceutical Research │ 7 (4),pp.339-346 (Co-authored)
176.	1990/01	Alteration of biopharmaceutical properties of drugs by their conjugation with water-soluble macromolecules: Uricase-dextran conjugates. │ Journal of Controlled Release │ 11 (1-3),pp.149-156 (Co-authored)
177.	1989/03	Control of pharmaceutical properties of soybean trypsin inhibitor by conjugation with dextran II: Biopharmaceutical and pharmacological properties. │ Journal of Pharmaceutical Sciences │ 74 (3),pp.219-222 (Co-authored)
178.	1989/02	Control of pharmaceutical properties of soybean trypsin inhibitor by conjugation with dextran I: Synthesis and characterization. │ Journal of Pharmaceutical Sciences │ 74 (2),pp.117-121 (Co-authored)